Wednesday, 24 Apr 2019

You are here

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Researchers set out to assess the level of opioid use in the year preceding a TJR and overall among Medicare beneficiaries with advanced osteoarthritis and if there were geographical variations in rates of treatment with long-term opioid therapy in osteoarthritis.  (Citation source: https://buff.ly/2FZ5atJ)

An observational cohort study of 358,121 osteoarthritis patients undergoing total joint replacement (TJR) examined long‐term opioids (≥ 90 days in the 360‐day period immediately preceding TJR) use.

Over the study years (2011 to 2014) the proportion of TJR patients using long-term opioids remained relatively stable (16.8% in 2011, 16.8% in 2012, 16.6% in 2013, and 16.3% in 2014).

They found that the unadjusted mean % of long‐term opioid users varied widely across states, ranging from 8.9% (Minnesota) to 26.4% (Alabama).

PCPs access was only modestly associated with rates of long‐term opioid use, while access to rheumatologists was not associated with long‐term opioid use.

Statewide variation in long‐term opioid use in osteoarthritis was not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

 

 

 

Add new comment

More Like This

NIH Workshop on Unmet Needs in Osteoporosis

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

Smoking Not Protective Against Knee OA

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark. An inverse association between OA and smoking had been suggested by several previous studies and a recent meta-analysis.  

FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis

The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

Guidelines for Osteoporosis Management in Postmenopausal Women

New guidelines on the  "Pharmacologic Management of Osteoporosis in Postmenopausal Women," were presented March 25 at ENDO 2019 - The Endocrine Society Annual Meeting and simultaneously published online in the Journal of Clinical Endocrinology & Metabolism.